R&D Medicine’s blind spot: How clinical trials are failing women From insulin to immunotherapies, clinical trials have powered some of the most important medical breakthroughs of our time.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
R&D What to do when your grant application fails All hope should not be lost and an unsuccessful application doesn’t always mark the end of the road.
R&D Post-hype, pre-value: The real AI-pharma shift starts now The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.
R&D When is the superbug message going to bite? As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.
R&D From data to impact: How real-world evidence will transform ... Real-world evidence (RWE) has moved from the periphery to the centre of how healthcare decisions are made.
News AZ claims another win for Imfinzi in frontline liver cancer AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
